MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Milpharm Limited, Loperamide hydrochloride 2 mg Orodispersible Tablets, EL(26)A/23
Published: 5/11/2026Detected: 5/11/2026
Summary preview
Class 4 defect notification addressed to Milpharm Limited highlights a discrepancy in the previously approved Patient Information Leaflet (PIL) for loperamide hydrochloride 2 mg orodispersible tablets.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountgastroenterology
labeling
safety
quality
#MHRA
#Class 4
#defect notification
#patient information leaflet
#PIL
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
- Field Safety Notices: 21 to 25 September 20269/29/2026
- MHRA Safety Roundup: September 20269/29/2026
- Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
- Field Safety Notices: 14 to 18 September 20269/23/2026